Intravitreal 4D-150

ASRS Data Discussion

PRISM

July 2024

Forward-Looking Statements

This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial position, prospects, plans, and objectives of management, are forward looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation.

This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied.

This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

4D-150 Population Extension Data Discussion Points

1. **Long term durability update expected in September at a medical conference (52-landmark guidance on Dose Expansion & Population Extension Cohorts in February 2025 remains unchanged)**
2. **Inclusion of Week 4 loading dose**
3. **Wet AMD is a heterogenous patient population**
4. **CST curve**
5. **Consistency of Safety Data**

Data cutoff date, June 24, 2024.

Loading Doses for Phase 3-Ready Long-Acting wet AMD Agents: 2nd Anti-VEGF Loading Dose as Phase 3 Approaches is **Industry Standard**

*Dose after Study Treatment

Asset (Mechanism)	Study Name	Phase	Total Loading Doses
ABBV-RGX-314 SR Gene Therapy	ATMOSPHERE/ASCENT	3	**3***
ABBV-RGX-314 SCS Gene Therapy	AAVIATE	2	**3***
AXPAXLI TKI implant	SOL-1	3	**2**
	SOL-R	3	**5**
DURAVYU TKI implant	DAVIO2	2	**3**
	LUGANO/ LUCIA	3	**3**
4D-150 IVT Gene Therapy	PRISM	2	**2***

Phase 2 Population Extension Cohort Treatment Schema & Endpoints

Population Extension Cohort Study Schema

Design Finalized ~Mid-2023:
1) Patient safety during gene expression ramp-up (maximizes by week 8-12)
2) Similar to expected Phase 3 design (and precedents)



Key Endpoints

- Safety and tolerability
- Annualized anti-VEGF injection rate
- % requiring supplemental aflibercept injection
- Change from baseline in BCVA and CST

Supplemental Injection Criteria

- BCVA: Loss of ≥10 letters from average of Day -7 and Day 1 attributable to retinal fluid
- CST: Increase ≥75 µm from average of Day -7 and Day 1 values
- New vision-threatening hemorrhage due to wet AMD per investigator

*Participants received one of: (a) difluprednate (Durezol) ophthalmic emulsion (3E10 & 1E10 vg/eye), (b) triamcinolone acetonide with prednisolone taper (3E10 vg/eye), or (c) dexamethasone (3E10 vg/eye). †Visual acuity, optical coherence tomography, ophthalmic exam.

Wet AMD Patients is a **Heterogenous** Patient Population with Varying Anti-VEGF Needs

Real World Injection Frequency[1]



1. Adapted from Ciulla et al: Ophthalmol Retina. 2020 Jan;4(1):19-30.; n = 49,485 eye.

Robust Anti-VEGF Treatment Burden Reduction Observed through 24 Weeks

Patients Receiving Planned Phase 3 Dose of 3E10: 77% Injection-Free & 93% Had 0–1 Injection



Overall:

89% reduction in annualized anti-VEGF injection rate

93% 0–1 injection

77% injection-free

23% injection (+)

9 of 11 (82%) "Recently Dx" patients were injection-free

Data cutoff date, June 24, 2024. *Scheduled on-study aflibercept injection administered at Weeks -1 and 4; post-4D-150 annualized anti-VEGF injection rate calculated from Week 4 onward (time of last loading aflibercept dose)

Planned Phase 3 Dose Demonstrated Sustained & Greater Anatomic Control Without Fluctuations, Including in Injection-Free Patients



Average (95% CI):	Baseline	Mean Change Weeks 20/24	Mean Absolute Week 24
3E10 vg/eye: Total	336	–9.2 (–30.8, 12.4)	326
3E10 vg/eye: Injection-free	333	–31.7 (–51.8, –11.6)	308

Data cutoff date, June 24, 2024.
Adjusted mean and 95% CI estimated from a mixed–effect model for repeated measures (MMRM) including observed data (weeks 4-24) without imputing missing values.
CI, confidence interval; CST, central subfield thickness.

4D-150 Continues to be Safe and Well Tolerated in Wet AMD & DME (N=139)

No Significant Inflammation in Patients Treated with Planned Phase 3 Dose & Durezol Regimen

Highest SUN/NEI Score Observed*

All Doses & Steroid Regimens Tested†
(5E9 to 3E10 vg/eye, N=139)



Includes DME (N=22): No inflammation, completed topical steroid prophylactic regimen on schedule and did not resume

Planned Phase 3 Dose & Durezol Regimen
(3E10 vg/eye, N=51)



No recurrent inflammation post local steroid taper

Range of Maximum Follow-up†
(5E9 to 3E10 vg/eye, N=139)



No 4D-150–related hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions observed to date

Data cutoff date, June 24, 2024.
*Duration of follow up, ≤2.5 years. NEI, National Eye Institute; SUN, Standardization of Uveitis Nomenclature. †N=29 3E10 vg/eye patients received one of the following: (a) triamcinolone acetonide with prednisolone taper or (b) dexamethasone.

Key Highlights from 4D-150 Interim Data Presented at ASRS

1. **STRONG CLINICAL ACTIVITY DEMONSTRATED IN BROAD WET AMD DISEASE ACTIVITY POPULATION:**
   Planned Phase 3 Population

2. **DEMONSTRATED DURABLE CLINICAL ACTIVITY**

3. **CONTINUES TO BE SAFE & WELL-TOLERATED:**
   In Both Wet AMD & DME

4. **PROVIDES FURTHER SUPPORT FOR PLANNED WET AMD PHASE 3 PROGRAM**

Data cutoff date, June 24, 2024.

THANK YOU

5858 Horton Street, Suite 455 | Emeryville, California 94608

(510) 505-2680 | Investor.Relations@4DMT.com

IR.4DMT.com | LinkedIn